Pomerantz Law Firm Opens Investigation Into Omeros Corporation on Behalf of Investors
Pomerantz LLP, a law firm specializing in securities litigation, announced Tuesday it is investigating claims on behalf of investors of Omeros Corporation, a company trading on the Nasdaq exchange under the ticker symbol OMER. The New York-based firm has invited affected shareholders to come forward as it examines potential legal claims against the biopharmaceutical company.
Pomerantz LLP, a law firm specializing in securities litigation, announced Tuesday it is investigating claims on behalf of investors of Omeros Corporation, a company trading on the Nasdaq exchange under the ticker symbol OMER. The New York-based firm has invited affected shareholders to come forward as it examines potential legal claims against the biopharmaceutical company.
Scope of the Investigation
Pomerantz LLP disclosed the investigation in a release dated July 1, 2026, without specifying the nature of the underlying claims or the time period under review. The firm did not identify any particular transactions, corporate disclosures, or events that triggered the inquiry. Investors holding positions in Omeros Corporation are the primary subjects of the firm's outreach.
The investigation follows a pattern common in securities law, where firms solicit shareholder contact ahead of a potential class action filing. No lawsuit has been announced at this stage.
How Investors Can Respond
Pomerantz directed investors to contact Danielle Peyton, identified as the point of contact for this matter. Peyton can be reached by email at [email protected] or by phone at 646-581-9980, extension 7980.
The firm did not disclose a deadline for investors to make contact, nor did it specify minimum holding requirements or the class period under consideration.
What This Means for OMER Shareholders
Securities investigations by plaintiff law firms can precede formal class action complaints, which typically allege that a company or its executives misled investors through false or misleading statements. The announcement alone carries no legal finding or determination of wrongdoing against Omeros Corporation.
Shareholders who believe they incurred losses on Omeros stock are the intended audience for Pomerantz's outreach. The firm provided no guidance on potential damages, estimated class size, or the expected timeline for any subsequent legal action.
Omeros Corporation has not been quoted in the source material responding to the investigation. The company trades on the Nasdaq under the symbol OMER.